MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-17-2026
West Pharmaceutical Services Operating Income 2011-2026 | WST
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income West Pharmaceutical Services
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 585 M | 570 M | 676 M | 734 M | 752 M | 407 M | 297 M | 240 M | 226 M | 195 M | 129 M | 182 M | 162 M | 135 M | 110 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 752 M | 110 M | 360 M |
Quarterly Operating Income West Pharmaceutical Services
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 168 M | 154 M | 107 M | - | 161 M | 126 M | 123 M | - | 177 M | 182 M | 155 M | - | 186 M | 228 M | 190 M | - | 181 M | 211 M | 176 M | - | 99.2 M | 104 M | 88 M | - | 67.3 M | 80.5 M | 70.7 M | - | 60.8 M | 60.3 M | 53.4 M | - | 62.9 M | 42 M | 60.5 M | - | 51.3 M | 61.2 M | 30 M | - | -3.5 M | 39.1 M | 47.8 M | - | 44 M | 54.1 M | 39.3 M | - | 39.7 M | 42.5 M | 43.3 M | - | 26.3 M | 35.6 M | 41.7 M | - | 26.1 M | 27.8 M | 28.8 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 228 M | -3.5 M | 90 M |
Operating Income of other stocks in the Medical instruments industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Atrion Corporation
ATRI
|
22.6 K | - | - | $ 810 M |  USA |
 |
Becton, Dickinson and Company
BDX
|
2.58 B | $ 154.51 | -1.17 % | $ 44.4 B | USA |
 |
Ekso Bionics Holdings
EKSO
|
-13.3 M | $ 9.4 | -11.74 % | $ 22.8 M | USA |
 |
Haemonetics Corporation
HAE
|
222 M | $ 56.83 | 1.05 % | $ 2.86 B | USA |
 |
Harvard Bioscience
HBIO
|
-48.6 M | $ 5.2 | 2.16 % | $ 231 M | USA |
 |
ICU Medical
ICUI
|
42.8 M | $ 123.31 | -1.53 % | $ 3.04 B | USA |
 |
AngioDynamics
ANGO
|
-40 M | $ 10.31 | -13.65 % | $ 421 M | USA |
 |
Isoray
ISR
|
-114 M | - | 0.03 % | $ 108 M | USA |
 |
Intuitive Surgical
ISRG
|
2.95 B | $ 452.07 | -2.67 % | $ 161 B | USA |
 |
AtriCure
ATRC
|
-9.45 M | $ 29.07 | 2.68 % | $ 1.39 B | USA |
 |
Repro Med Systems
KRMD
|
-2.97 M | $ 4.32 | 1.17 % | $ 200 M | USA |
 |
InfuSystem Holdings
INFU
|
1.65 M | $ 9.29 | -0.11 % | $ 192 M | USA |
 |
iRhythm Technologies
IRTC
|
-57.4 M | $ 116.8 | -1.2 % | $ 3.74 B | USA |
 |
Masimo Corporation
MASI
|
-267 M | $ 178.59 | 0.33 % | $ 9.52 B | USA |
 |
BioLife Solutions
BLFS
|
-7.13 M | $ 19.51 | 1.14 % | $ 899 M | USA |
 |
Merit Medical Systems
MMSI
|
185 M | $ 67.7 | -0.78 % | $ 4 B | USA |
 |
electroCore
ECOR
|
-13.2 M | $ 6.8 | 3.03 % | $ 57.7 K | USA |
 |
OraSure Technologies
OSUR
|
-72 M | $ 3.08 | 0.98 % | $ 226 M | USA |
 |
Glaukos Corporation
GKOS
|
-129 M | $ 112.77 | 0.12 % | $ 5.46 B | USA |
 |
Pulse Biosciences
PLSE
|
-76.9 M | $ 23.0 | -0.13 % | $ 1.55 B | USA |
 |
Predictive Oncology
POAI
|
-181 M | - | - | $ 31.1 M | USA |
 |
Repligen Corporation
RGEN
|
47.7 M | $ 117.78 | -0.46 % | $ 6.56 M | USA |
 |
Baxter International
BAX
|
-308 M | $ 16.68 | -0.6 % | $ 8.56 B | USA |
 |
ResMed
RMD
|
1 B | $ 224.09 | 0.56 % | $ 32.7 B | USA |
 |
NeuroMetrix
NURO
|
-8.78 M | - | 5.05 % | $ 9.02 M | USA |
 |
STERIS plc
STE
|
867 M | $ 218.71 | -0.56 % | $ 21.6 B | USA |
 |
STAAR Surgical Company
STAA
|
-91.7 M | $ 20.21 | 4.55 % | $ 1 B | USA |
 |
Stereotaxis
STXS
|
-22.1 M | $ 1.87 | 1.08 % | $ 170 M | USA |
 |
Teleflex Incorporated
TFX
|
13.9 M | $ 117.81 | -0.52 % | $ 5.26 B | USA |
 |
The Cooper Companies
COO
|
683 M | $ 70.17 | -1.76 % | $ 14 B | USA |
 |
Utah Medical Products
UTMD
|
11.4 M | $ 63.12 | 0.4 % | $ 205 M | USA |
 |
DENTSPLY SIRONA
XRAY
|
-422 M | $ 11.63 | -0.26 % | $ 2.32 B | USA |
 |
LeMaitre Vascular
LMAT
|
67.9 M | $ 108.49 | -0.24 % | $ 2.46 B | USA |
 |
Microbot Medical
MBOT
|
-14.7 M | $ 2.4 | 1.27 % | $ 110 M |  Israel |
 |
Nephros
NEPH
|
-1.59 M | $ 2.87 | -2.21 % | $ 29.8 M | USA |
 |
Envista Holdings Corporation
NVST
|
216 M | $ 25.81 | -0.35 % | $ 4.34 B | USA |
 |
Milestone Scientific
MLSS
|
-5.7 M | $ 0.28 | -4.86 % | $ 23 M | USA |
 |
Alcon
ALC
|
580 M | $ 74.56 | -1.26 % | $ 40.4 B |  Schweiz |
 |
Pro-Dex
PDEX
|
10.7 M | $ 51.67 | 1.33 % | $ 170 M | USA |
 |
Retractable Technologies
RVP
|
-21.2 M | $ 0.69 | 2.99 % | $ 20.7 M | USA |